The short version of dual agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-08. Anything still debated is marked as such rather than presented as settled.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid form |
| Purity assay | 95 percent or greater by RP-HPLC | Typical research-grade specification |
| Storage temperature | 2 to 8 degrees Celsius | Formulated solution, do not freeze |
| Common analytical method | LC-MS with peptide mapping | Identity and impurity confirmation |
| Primary degradation routes | Deamidation, oxidation, aggregation | Tracked in stability programs |
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
Clean road, rail, sea and air transport are fundamental goals of the EU, given its commitment to human rights for 'improvement of the quality of the environment', 'services of general economic interest', and the right to 'the benefits of scientific progress'. However, the pace of reform is slow compared to the urgency of reversing global heating. The Renewable Energy Directive 2018 article 25 requires that final energy consumption in transport in each member state is 'at least 14%' renewable by 2030. This is within the 2030 target for 32% "share of energy from renewable sources in the Union's gross final consumption of energy". In 2022, the EU promised to ban sale of new petrol and diesel vehicles only by 2035, enabling manufacturing corporations to profit from toxic emissions for another 13 years, though many member states have higher standards. There is not yet a plan for full rail electrification, or clean shipping or air travel, even where technology exists.
== External links == "Fibrodysplasia Ossificans Progressiva (FOP)". The College of Physicians of Philadelphia Digital Library. Digitized by the Mütter Museum of The College of Physicians of Philadelphia. Retrieved November 28, 2018.
==== Extraterrestrial ==== PAHs are prevalent in the interstellar medium (ISM) of galaxies in both the nearby and distant Universe and make up a dominant emission mechanism in the mid-infrared wavelength range, containing as much as 10% of the total integrated infrared luminosity of galaxies. PAHs generally trace regions of cold molecular gas, which are optimum environments for the formation of stars. NASA's Spitzer Space Telescope and James Webb Space Telescope include instruments for obtaining both images and spectra of light emitted by PAHs associated with star formation. These images can trace the surface of star-forming clouds in our own galaxy or identify star forming galaxies in the distant universe. In June 2013, PAHs were detected in the upper atmosphere of Titan, the largest moon of the planet Saturn.
== Reference pattern == This reference pattern is based on the essential amino acid requirements for preschool children aged 1–3 years as published in Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (2005). Adults aged 18+ will have slightly lower requirements.
==== Aerospace ==== In April 1972 Heseltine was promoted to be minister for aerospace, a minister of state rather than a Cabinet minister but effectively running his own department within the Department of Trade and Industry, another of Heath's new mega ministries. The department had been given major new powers by the 1972 Industry Act. Later in the year Peter Walker was appointed Secretary of State for Trade and Industry, making him Heseltine's boss once again. Heseltine appointed Cecil Parkinson, whom he had met on an accountancy course in the mid-1950s, as his Parliamentary Private Secretary, ostensibly on the grounds that he knew even less about aerospace than he did. Parkinson was impressed by Heseltine's vigour and his insistence that civil servants produce results for him quickly, later writing in his memoirs (1992) "in his constructive and deliberate unreasonableness he reminds me in many ways of Mrs Thatcher". Heseltine arguably did not make aerospace policy any more interventionist than it already was. One of Heseltine's main jobs was to sell Concorde, which was difficult because of its cost and limited range (it could fly from New York to London or Paris, but not the short extra distance to Rome or Frankfurt) and capacity (a quarter that of a Boeing 747). It had been initiated by Macmillan in 1962 as an Anglo-French project to try to get Britain into the EEC, although by the early 1970s Heath was already broaching cancellation with President Pompidou.
Sources: en.wikipedia.org
== Myths == A common myth among radar and microwave communication workers is that the exposure of the genital area to microwaves renders a man sterile for about a day. The power density necessary for this effect is however sufficient to also cause permanent damage.
== History == A digital ion trap (DIT) is an ion trap having a trapping waveform generated by the rapid switching between discrete high-voltage levels. The timing of the high voltage switch is controlled precisely with digital electronic circuitry. Ion motion in a quadrupole ion trap driven by a rectangular wave signal was theoretically studied in 1970s by Sheretov, E.P. and Richards, J.A. Sheretov also implemented the pulsed waveform drive for the quadrupole ion trap working in mass-selective instability mode, although no resonance excitation/ejection was used. The idea was substantially revisited by Ding L. and Kumashiro S. in 1999, where the ion stability in the rectangular wave quadrupole field was mapped in the Mathieu space a-q coordinate system, with the parameters a and q having the same definition as the Mathieu parameters normally used in dealing with sinusoidal RF driven quadrupole field. The secular frequency dependence on the a, q parameters was also derived thus the foundation was laid for many modern ion trap operation modes based on the resonance excitation. Also, in 1999, Peter T.A. Reilly began trapping and subsequently ablating and mass analyzing the product ions from nanoparticles obtained from car exhaust with a primitive hybrid square wave/sine wave driven 3D ion trap. In 2001 Reilly attended the 49th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Applied Topics where he presented his nanoparticle mass analysis work and met Li Ding for the first time.
=== Final months === In 2004, the team returned after Christmas to long hours, stressful working conditions, and no guarantee that Half-Life 2, which was costing $1 million a month to develop, would be finished soon. However, Newell felt that momentum was gathering, with the team producing about three hours of gameplay per month. In March, they created the first version playable from start to finish and stopped development for a week to play through. Major changes by this point included the cutting of the Borealis, the replacement of the jet ski with an airboat, and introducing the physics-manipulating gravity gun earlier. Feedback was positive across the company. Newell recalled: "The fact that you could go from one end of the game to the other was a really big thing for us. Then we knew it just had to get better – but it was all there." After several months of bug fixes and playtesting, Half-Life 2 was completed on October 13, 2004.
Valproate is a weak or low-potency histone deacetylase inhibitor, specifically of the class I HDAC1, HDAC2, HDAC3, and HDAC8, but not of other HDACs. Earlier studies found a wide range of inhibitory potencies of valproate against HDACs, ranging from low micromolar to millimolar concentrations, but subsequent work with improved methodology has supported greater inhibitory potencies, with IC50Tooltip half-maximal inhibitory concentration values in the range of 36 to 219 μM for the class I HDACs. For comparison, valproate was found to be 4- to 46-fold less potent in inhibiting the class I HDACs relative to butyric acid (butyrate). By inhibiting HDACs, valproate promotes more transcriptionally active chromatin structures, that is it exerts an epigenetic effect. This has been proven in mice: Valproic acid induced histone hyperacetylation had brain function effects on the next generation of mice through changes in sperm DNA methylation. Intermediate molecules include VEGF, BDNF, and GDNF.
Sources: en.wikipedia.org
Reversed-phase high-performance liquid chromatography is the standard approach, separating the main peak from related impurities. Ultraviolet detection near 214 nanometers captures the peptide backbone. Mass spectrometry is then used alongside chromatography to confirm identity and detect covalent modifications.
Cycling between frozen and liquid states concentrates the peptide at ice interfaces, which favors non-covalent association. The resulting aggregates may be invisible to simple assays yet alter recovery and apparent potency. Limiting the number of cycles and aliquoting before storage are common mitigations.
Tryptophan and methionine side chains can undergo photo-induced oxidation, so amber glass or opaque packaging is typical. The effect is gradual and depends on wavelength and exposure time. Light protection is usually specified for both solid and solution forms.
It separates molecules by hydrophobicity, which is effective for distinguishing an intact peptide from truncated or chemically modified forms. A C18 column with an acidic water-organic mobile phase is a standard configuration.